Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 Allelic isoforms

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 3, 2002, Pages 1291-1300

  Yu, Aiming ^a   Kneller, Byron M ^b   Rettie, Allan E ^b   Haining, Robert L ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; CYTOCHROME P450 2D6; CYTOCHROME P450 2D6 1; CYTOCHROME P450 2D6 10; CYTOCHROME P450 2D6 17; CYTOCHROME P450 2D6 2; CYTOCHROME P450 REDUCTASE; DEXTROMETHORPHAN; N DEMETHYLASE; O DEMETHYLASE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CATALYSIS; CATALYST; CONTROLLED STUDY; DEMETHYLATION; GENE LOCUS; GENETIC VARIABILITY; HUMAN; HYPOTHESIS; IN VITRO STUDY; KINETICS; MASS SPECTROMETRY; PHARMACOGENETICS; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; PROTEIN PURIFICATION; REACTION TIME; SPECTROSCOPY;

ALLELES; ANIMALS; BACULOVIRIDAE; CYTOCHROME P-450 CYP2D6; DNA, COMPLEMENTARY; ENZYME ACTIVATION; HUMANS; ISOENZYMES; MOTHS; SUBSTRATE SPECIFICITY;

EID: 0036897469     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.039891     Document Type: Article

References (44)

1. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, and Ingelman-Sundberg M (1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278:441-446.
2. Ching MS, Blake CL, Ghabrial H, Ellis SW, Lennard MS, Tucker GT, and Smallwood RA (1995) Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine and its metabolites. Biochem Pharmacol 50:833-837.
3. Daly AK (1995) Molecular basis of polymorphic drug metabolism. J Mol Med 73:539-553.
4. Droll K, Bruce-Mensah K, Otton SV, Gaedigk A, Sellers EM, and Tyndale RF (1998) Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics 8:325-333.
5. Evans WE and Relling MV (1999) Pharmacogenomics: Translating functional genomics into rational therapeutics. Science (Wash DC) 286:487-491.
6. Fonne-Pfister R, Bargetzi MJ, and Meyer UA (1987) MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 148:1144-1150.
7. Fukuda T, Nidhida Y, Imaoka S, Hiroi T, Naohara M, Funae Y, and Azuma J (2000) The decreased in vivo clearance of CYP2D6 substrateds by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch Biochem Biophys 380:303-308.
8. Garcia-Barcelo M, Chow LY, Chiu HF, Wing YK, Lee DT, Lam KL, and Waye MM (2000) Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem 46:18-23.
9. Gilham DE, Cairns W, Paine MJI, Modi S, Poulsom R, Roberts GCK, and Wolf CR (1997) Metabolism of MPTP by cytochrome P450 2D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 27:111-125.
10. Gonzalez FJ and Nebert DW (1990) Evolution of the P450 gene superfamily: Animalplant "warfare", molecular drive and human genetic differences in drug oxidation. Trends Genet 6:182-186.
11. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, and Meyer UA (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (Lond) 331:442-446.
12. Gotoh O (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83-90.
13. Haining RL, Hunter AP, Veronese ME, Trager WF, and Rettie AE (1996) Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 333:447-458.
14. Idle JR and Smith RL (1979) Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab Rev 9:301-317.
15. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjqvist F, and Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P450 2D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459.
16. Kimura S, Umeno M, Skoda RC, Meyer UA, and Gonzalez FJ (1989) The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. Am J Hum Genet 45:889-904.
17. Kleyn PW and Vesell ES (1998) Genetic variation as a guide to drug development. Science (Wash DC) 281:1820-1821.
18. Koenigs LL, Hunter AP, Peter RM, Haining RL, Friedberg T, Pritchard M, Rushmore T, Shou M, and Trager WF (1999) Electrospray ionization mass spectrometric analysis of intact cytochrome P450: Identification of tienilic acid adducts to P450 2C9. Biochemistry 38:2312-2319.
19. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
20. Krynetski EY, Drutsa VL, Kovaleva IE, and Luzikov VN (1995) High yield expression of functionally active human liver CYP2D6 in yeast cells. Pharmacogenetics 5:103-109.
21. Leathart JB, London SJ, Steward A, Adams JD, Idle JR, and Daly AK (1998) CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 8:529-541.
22. Marcucci KA, Pearce RE, Crespi C, Steimel DT, Leeder JS, and Gaedigk A (2002) Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2 and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol and debrisoquine. Drug Metab Dispos 30:595-601.
23. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, Meyer UA, and Broly F (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193-202.
24. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, and Obach RS (2000) (R)-, (S) and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos 28:1187-1191.
25. Masimirembwa C, Persson I, Bertilsson L, Hasler J, and Ingelman-Sundberg M (1996) A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 42:713-719.
26. Nebert DW (1997) Polymorphisms in drug-metabolizing enzymes: What is their clinical relevance and why do they exist. Am J Hum Genet 60:265-271.
27. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
28. O'Reilly DR, Miller LK, and Luckow VA (1994) Baculovirus Expression Vectors - A Laboratory Manual, Oxford University Press, New York.
29. Oscarson M, Hidestrand M, Johansson I, and Ingelaman-sundberg M (1997) A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 52:1034-1040.
30. Panserat S, Sica L, Gerard N, Mathieu H, Jacqz-Aigrain E, and Krishnamoorthy R (1999) CYP2D6 polymorphism in a Gabonese population: Contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype. Br J Clin Pharmacol 47:121-124.
31. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, and Zanger UM (2000) Elucidation of the genetic basis of the common "intermediate metabolizer" phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10:577-581.
32. Sachse C, Brockmller J, Baner S, and Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295.
33. Sambrook J, Fritsch EF, and Maniatis T (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
34. Shen AL, Christensen MJ, and Kasper CB (1991) NADPH-cytochrome P-450 oxidoreductase. The role of cysteine 566 in catalysis and cofactor binding. J Biol Chem 266:19976-19980.
35. Shimada T, Tsumura F, Yamazaki H, Guengerich FP, and Inoue K (2001) Characterization of (±)-bufuralol hydroxylation activities in liver microsomes & Japanese and Caucasian subjects genotyped for CYP2D6. Pharmacogenetics 11:143-156.
36. Tateishi T, Chida M, Ariyochi N, Mizorogi Y, Kamataki T, and Kobayashi S (1999) Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 65:570-575.
37. Teh LK, Ismail R, Yusoff R, Hussein A, Isa MN, and Rahman AR (2001) Heterogeneity of the CYP2D6 gene among Malays in Malaysia. J Clin Pharm Ther 26:205-211.
38. Tsuzuki D, Takemi C, Yamamoto S, Tamagake K, Imaoka S, Funae Y, Kataoka H, Shinoda S, and Narimatsu S (2001) Functional evaluation of cytochrome P450 2D6 with Gly42 Arg substitution expressed in Saccharomyces cerevisiae. Pharmacogenetics 11:709-718.
39. Wan YJ, Poland RE, Han G, Konishi T, Zheng YP, Berman N, and Lin KM (2001) Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics 11:489-499.
40. Wennerholm A, Johansson I, Massele AY, Lande M, Alm C, Aden-Abdi Y, Dahl ML, Ingelman-Sundberg M, Bertilsson L, and Gustafsson LL (1999) Decreased capacity for debrisoquine metabolism among black Tanzanians: Analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics 9:707-714.
41. Yamazaki S, Sato K, Suhara K, Sakaguchi M, Mihara K, and Omura T (1993) Importance of the proline-rich region following signal-anchor sequence in the formation of correct conformation of microsomal cytochrome P-450s. J Biochem (Tokyo) 114:652-657.
42. Yu A, Dong H, Dieter L, and Haining RL (2001) Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. Drug Metab Dispos 29:1362-1365.
43. Yu A and Haining RL (2001) Can dextromethorphan be used as a dual probe for both CYP2D6 and CYP3A activities? Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro. Drug Metab Dispos 29:1514-1520.
44. Zanger UM, Fischer J, Raimundo S, Stuven T, Evert BO, Schwab M, and Eichelbaum M (2001) Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11:573-585.